C.A. Papaellinas undertakes the full representation of the global Sanofi biopharmaceutical company in Cyprus

By 2 August 2021 News, Press

C.A. Papaellinas is advancing with a particularly important business agreement: the full representation of the global Sanofi biopharmaceutical company in Cyprus.

Sanofi develops innovative therapeutic products in specialized medical categories such as: rare diseases, Multiple Sclerosis, Oncology, Immunology, Infectious diseases, Diabetes and Cardiology.

Alongside the distribution of medicine as part of the collaboration with Sanofi, the Group is also responsible for providing Health Professionals in Cyprus with scientific information about Sanofi pharmaceutical products.

This business development reflects Sanofi’s increased trust in the C.A. Papaellinas Group – a collaboration which brings forth a new opportunity for improving the quality of life of patients, while also keeping Health Professionals up to date with relevant scientific information. This constitutes a cornerstone of our mission: to make even more people live and feel better.